Summary

Eligibility
for people ages 40 years and up (full criteria)
Location
at UCSF
Dates
study started
study ends around

Description

Summary

This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.

Official Title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis

Details

This is randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.

Keywords

Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Fibrosis, DWN12088, DWN12088 Xmg Tablet (BID)

Eligibility

Locations

  • The University of California San Francisco accepting new patients
    San Francisco California 94143 United States
  • Dignity Health Norton Thoracic Institute accepting new patients
    Phoenix Arizona 85013 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Daewoong Pharmaceutical Co. LTD.
ID
NCT05389215
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 102 study participants
Last Updated